NOV human
SIGMA/SRP3125 - recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture
Synonym: CCN3; IGFBP9; Nephroblastoma Overexpressed Gene; NovH
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| assay | ≥95% (HPLC) |
| ≥95% (SDS-PAGE) | |
| biological source | human |
| color | white to off-white |
| form | lyophilized |
| impurities | <0.1 EU/μg endotoxin, tested |
| mol wt | 36.2 kDa |
| packaging | pkg of 20 μg |
| potency | 1.0-2.0 μg/mL ED50 |
| recombinant | expressed in E. coli |
| shipped in | wet ice |
| storage temp. | −20°C |
| technique(s) | cell culture | mammalian: suitable |
| UniProt accession no. | P42642   |
| Biochem/physiol Actions: | NOV is a member of the CCN family of secreted cysteine rich regulatory proteins. Recombinant human NOV is a 36.2 kDa protein containing 331 amino acid residues. It is composed of four distinct structural domains (modules); the IGF binding protein (IGFBP) domain, the von Willebrand Factor C (VWFC) domain, the Thrombospondin type-I (TSP type-1) domain, and a C-terminal cysteine knot-like domain (CTCK). |
| General description: | NOV is a member of the CCN family of secreted cysteine rich regulatory proteins. The full length NOV protein contains four structural domains that confer distinct, and sometimes opposing, biological activities. Elevated expression of NOV is associated with certain tumors, including Wilm’s tumor and most nephroblastomas. However, in other tumor types and certain cancer cell lines, increased tumorgenicity and proliferation is correlated with decreased NOV expression. Additionally, NOV induces cell adhesion and cell migration by signaling through specific cell surface integrins and by binding to heparin sulfate proteoglycans and to fibulin 1C. NOV has also been reported to exert proangiogenic activities. Recombinant human NOV is a 36.2 kDa protein containing 331 amino acid residues. It is composed of four distinct structural domains (modules); the IGF binding protein (IGFBP) domain, the von Willebrand Factor C (VWFC) domain, the Thrombospondin type-I (TSP type-1) domain, and a C-terminal cysteine knot-like domain (CTCK). |
| Other Notes: | MQVAATQRCP PQCPGRCPAT PPTCAPGVRA VLDGCSCCLV CARQRGESCS DLEPCDESSG LYCDRSADPS NQTGICTAVE GDNCVFDGVI YRSGEKFQPS CKFQCTCRDG QIGCVPRCQL DVLLPEPNCP APRKVEVPGE CCEKWICGPD EEDSLGGLTL AAYRPEATLG VEVSDSSVNC IEQTTEWTAC SKSCGMGFST RVTNRNRQCE MLKQTRLCMV RPCEQEPEQP TDKKGKKCLR TKKSLKAIHL QFKNCTSLHT YKPRFCGVCS DGRCCTPHNT KTIQAEFQCS PGQIVKKPVM VIGTCTCHTN CPKNNEAFLQ ELELKTTRGK M |
| Physical form: | Lyophilized from 10 mM Sodium Phosphate, pH 7.5. |
| Preparation Note: | Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (HPLC); ≥95% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |